Sanofi and GSK seek approval for Covid-19 vaccine

The drugmakers hope to catch up with rivals after reporting positive results from late-stage clinical trials

The French and British drugmakers Sanofi and GSK are ready to seek approval from regulators for their Covid-19 vaccine after reporting positive results from late-stage clinical trials.

The firms are hoping to catch up with rivals after falling far behind in the race to develop Covid-19 shots. Their product was delayed by an early dosing error during trials, initially disappointing results in older people and other issues. It will be available as a two-dose vaccine and as a booster.